APOBEC3F

Revision as of 13:59, 4 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F
Identifiers
Symbols APOBEC3F ; ARP8; BK150C2.4.MRNA; KA6; MGC74891
External IDs Template:OMIM5 Template:MGI HomoloGene: 81935
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F, also known as APOBEC3F, is a human gene.[1]

This gene is a member of the cytidine deaminase gene family. It is one of seven related genes or pseudogenes found in a cluster, thought to result from gene duplication, on chromosome 22. Members of the cluster encode proteins that are structurally and functionally related to the C to U RNA-editing cytidine deaminase APOBEC1. It is thought that the proteins may be RNA editing enzymes and have roles in growth or cell cycle control. Alternatively spliced transcript variants encoding different isoforms have been identified.[1]

References

  1. ↑ 1.0 1.1 "Entrez Gene: APOBEC3F apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F".

Further reading

  • Wedekind JE, Dance GS, Sowden MP, Smith HC (2003). "Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business". Trends Genet. 19 (4): 207–16. PMID 12683974.
  • Franca R, Spadari S, Maga G (2006). "APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism". Med. Sci. Monit. 12 (5): RA92–8. PMID 16641889.
  • Prashar Y, Weissman SM (1996). "Analysis of differential gene expression by display of 3' end restriction fragments of cDNAs". Proc. Natl. Acad. Sci. U.S.A. 93 (2): 659–63. PMID 8570611.
  • Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. PMID 8889548.
  • Dunham I, Shimizu N, Roe BA; et al. (1999). "The DNA sequence of human chromosome 22". Nature. 402 (6761): 489–95. doi:10.1038/990031. PMID 10591208.
  • Jarmuz A, Chester A, Bayliss J; et al. (2002). "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22". Genomics. 79 (3): 285–96. doi:10.1006/geno.2002.6718. PMID 11863358.
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
  • Zheng YH, Irwin D, Kurosu T; et al. (2004). "Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication". J. Virol. 78 (11): 6073–6. doi:10.1128/JVI.78.11.6073-6076.2004. PMID 15141007.
  • Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004). "A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins". EMBO J. 23 (12): 2451–8. doi:10.1038/sj.emboj.7600246. PMID 15152192.
  • Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004). "APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo". Curr. Biol. 14 (15): 1385–91. doi:10.1016/j.cub.2004.06.050. PMID 15296757.
  • Collins JE, Wright CL, Edwards CA; et al. (2005). "A genome annotation-driven approach to cloning the human ORFeome". Genome Biol. 5 (10): R84. doi:10.1186/gb-2004-5-10-r84. PMID 15461802.
  • Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334.
  • Haché G, Liddament MT, Harris RS (2005). "The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain". J. Biol. Chem. 280 (12): 10920–4. doi:10.1074/jbc.M500382200. PMID 15647250.
  • Kimura K, Wakamatsu A, Suzuki Y; et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMID 16344560.
  • Zennou V, Bieniasz PD (2006). "Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates". Virology. 349 (1): 31–40. doi:10.1016/j.virol.2005.12.035. PMID 16460778.
  • Tian C, Yu X, Zhang W; et al. (2006). "Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F". J. Virol. 80 (6): 3112–5. doi:10.1128/JVI.80.6.3112-3115.2006. PMID 16501124.
  • Stenglein MD, Harris RS (2006). "APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism". J. Biol. Chem. 281 (25): 16837–41. doi:10.1074/jbc.M602367200. PMID 16648136.
  • Wichroski MJ, Robb GB, Rana TM (2006). "Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies". PLoS Pathog. 2 (5): e41. doi:10.1371/journal.ppat.0020041. PMID 16699599.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=APOBEC3F&oldid=709498"